Abstracts Archive - Page 974 of 2607 - ACR Meeting Abstracts

Abstract Number: PP12 • ACR Convergence 2020
COVID-19, Racism, and Gender Discrimination: The Function of Stress in Widening the Gap in Health Disparities
Carly Harrison¹ and Christele Felix², ¹LupusChat, Richmond, VA, ²LupusChat, Rosedale, NY
Background/Purpose: Populations experiencing rheumatic diseases are often at higher risk of increased levels of stress. This may result in disease complications and can potentially lead…
Abstract Number: 001 • 2020 Pediatric Rheumatology Symposium
WITHDRAWN
Abstract Number: 002 • 2020 Pediatric Rheumatology Symposium
WITHDRAWN
Abstract Number: 003 • 2020 Pediatric Rheumatology Symposium
Implementing Treat to Target Approach in the Care of Juvenile Idiopathic Arthritis Across a Network of Pediatric Rheumatology Centers
Julia Harris¹, Esi Morgan ², Janalee Taylor ², Tingting Qiu ³, Nancy Griffin ³, Anne Paul ⁴, C. April Bingham ⁵, Danielle Bullock ⁶, Kerry Ferraro ⁷, Mileka Gilbert ⁸, Y. Ingrid Goh ⁹, Olha Halyabar ¹⁰, Karla Jones ¹¹, Melanie Kohlheim ¹², Daniel J. Lovell ¹³, Emily Smitherman ¹⁴, Anjie Vago ⁷, Jennifer Weiss ¹⁵, Cagri Yildirim-Toruner ¹¹, Angela Young ⁷, Michelle Batthish ¹⁶, Beth Gottlieb ¹⁷, Melissa Hazen ¹⁸, Ronald Laxer ¹⁹, Tzielan Lee ²⁰, Melissa Mannion ¹⁴, Judyann Olson ²¹, Michael Shishov ²², Salma Siddique ²³, Charles Spencer ²⁴, Mary Toth ²⁵, Sheetal Vora ²⁶ and Jon Burnham ²⁷, ¹Children's Mercy Kansas City, Overland Park, ²Cincinnati Children's Hospital, Cincinnati, ³Cincinnati Children's Hospital Medical Center, Cincinnati, ⁴Cincinnati Children's Hospital Medical Centre, Cincinnati, ⁵Penn State Children's Hospital, Allentown, ⁶University of Minnesota, Minneapolis, ⁷Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, ⁸Medical University of South Carolina, Charleston, South Carolina, ⁹The Hospital for Sick Children, Toronto, Canada, ¹⁰Children's Hospital/Boston Medical Center, Boston, ¹¹Nationwide Children's Hospital, Columbus, ¹², ¹³Cincinnati, ¹⁴University of Alabama at Birmingham, Birmingham, ¹⁵Hackensack University Medical Center, Hackensack, ¹⁶McMaster University, Hamilton, Canada, ¹⁷Cohen Children's Medical Center, Lake Success, ¹⁸Boston, ¹⁹The Hospital for Sick Children and University of Toronto, Toronto, Canada, ²⁰Stanford Children's, Palo Alto, ²¹Medical College of Wisconsin: Children's Wisconsin, Wauwatosa, Wisconsin, ²²Phoenix Children's Hospital, Phoenix, ²³Nemours/A.I.duPont Hospital for Children, Wilmington, ²⁴Jackson, ²⁵Nemours Foundation, Orlando, ²⁶Atrium Health Levine Children's Hospital, Charlotte, ²⁷Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: In 2018, an international task force published a recommended Treat to Target (T2T) approach to JIA treatment. This treatment paradigm involves setting a treatment…
Abstract Number: 004 • 2020 Pediatric Rheumatology Symposium
Implications of Adopting the Newly Proposed Pediatric Rheumatology International Trials Organization (PRINTO) Classification Criteria for Juvenile Idiopathic Arthritis (JIA): Results from the Research in Arthritis in Canadian Children, Emphasizing Outcomes (ReACCh-Out) Cohort
Jennifer Lee¹, Simon Eng ², Brian Feldman ³, Jaime Guzman ⁴, Kiem Oen ² and Rae Yeung ³, ¹University of Toronto, Toronto, Canada, ²Toronto, Canada, ³The Hospital for Sick Children, Toronto, Canada, ⁴University of British Columbia and BC Children's Hospital, Vancouver, Canada
Background/Purpose: PRINTO recently proposed preliminary JIA classification criteria to revise the International League of Associations for Rheumatology (ILAR) criteria. The stated aim was to obtain…
Abstract Number: 005 • 2020 Pediatric Rheumatology Symposium
Single Cell Sequencing of the Skin to Define Cell Populations of Interest in Localized Scleroderma (LS)
Emily Mirizio ¹, Wei Chen ², Tao Sun ², Tracy Tabib ³, Kaila Schollaert-Fitch ¹, Robert Lafyatis ⁴, Heidi Jacobe ⁵ and Kathryn Torok¹, ¹Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, ²Research Computing Core at Children's Hospital of Pittsburgh, Pittsburgh, ³Univ of Pittsburgh Med Ctr, Pittsburgh, ⁴Univ of Pittsburgh Med Ctr, Pittsburgh, Pittsburgh, ⁵University of Texas Southwestern Medical Ctr, Dallas
Background/Purpose: Scleroderma is an autoimmune disorder involving inflammatory driven fibrosis, which encompasses systemic sclerosis (SSc) and localized scleroderma (LS). LS and SSc share histological characteristics,…
Abstract Number: 006 • 2020 Pediatric Rheumatology Symposium
Increasing Rates of Standardized Depression Screening in Youth with Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic
Victoria Newsome ¹, Jodi Dingle ², Manda Mitchell ³, Thomas Brent Graham ⁴ and Alaina Davis⁵, ¹Nashville, ²Vanderbilt University Medical Center, Nashville, Tennessee, ³Nashville, Tennessee, ⁴Vanderbilt University Medical Center, Nashville, ⁵Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, Tennessee
Background/Purpose: Depression is common among youth with SLE. Early identification and treatment of depression has the potential to improve health outcomes for youth with SLE.…
Abstract Number: 007 • 2020 Pediatric Rheumatology Symposium
Dense Genotyping of Immunologic Loci Identifies CXCR4 as a Novel Susceptibility Locus for Systemic Juvenile Idiopathic Arthritis
Emily Shuldiner ¹, Elaine Remmers ², Miranda Marion ³, Marc Sudman ⁴, Colleen Satorius ⁵, International Childhood Arthritis Genetics Consortium (INCHARGE), Juvenile Arthritis Consortium for the Immunochip (JACI), Wendy Thomson ⁶, Michael Ombrello¹, Patricia Woo ⁷, Carl Langefeld ⁸, Sampath Prahalad ⁹ and Susan Thompson ¹⁰, ¹NIAMS, NIH, Bethesda, ²National Human Genome Research Institute, Bethesda, ³Wake Forest University, Winston-Salem, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵NHGRI, NIH, Bethesda, ⁶Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁷London, United Kingdom, ⁸Winston Salem, ⁹Emory + Children's Pediatric Institute, Atlanta, ¹⁰Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a severe, potentially lethal inflammatory condition. It accounts for a disproportionate share of morbidity and mortality among childhood…
Abstract Number: 008 • 2020 Pediatric Rheumatology Symposium
Incidence and Risk Factors of Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Pediatric Rheumatic Diseases
Mei-Sing Ong¹, Deborah Rothman ² and Marc Natter ³, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, ²Massachusetts General Hospital, Springfield, ³Boston Children's Hospital, Boston
Background/Purpose: B-cell depletion therapy has increasingly been used for the treatment of childhood-onset rheumatic diseases. Previous studies investigating whether rituximab results in increased infections have…
Abstract Number: 009 • 2020 Pediatric Rheumatology Symposium
Emapalumab (Anti-Interferon-Gamma Monoclonal Antibody) in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA)
Fabrizio De Benedetti¹, Paul Brogan ², Claudia Bracaglia ¹, Manuela Pardeo ¹, Giulia Marucci ¹, Emanuela Sacco ¹, Despina Eleftheriou ³, Charalampia Papadopoulou ³, Alexei Grom ⁴, Pierre Quartier ⁵, Rayfel Schneider ⁶, Philippe Jacqmin ⁷, Rikke Frederiksen ⁸, Maria Ballabio ⁹ and Cristina de Min ⁸, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ²UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ³UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Section Head Infection, Immunology, and Rheumatology, London, United Kingdom, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Paris-Descartes University, IMAGINE Institute, RAISE reference centre, Pediatric Immuno-Hematology and Rheumatology Unit, Necker hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁶The Hospital for Sick Children, Toronto, Canada, ⁷MnS Modelling and Simulation, Dinant, Belgium, ⁸Swedish Orphan Biovitrum AG (Sobi), Basel, Basel-Stadt, Switzerland, ⁹Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland
Background/Purpose: MAS is a severe complication of rheumatic diseases and occurs most frequently in patients with sJIA. Data from animal models and from observational studies…
Abstract Number: 010 • 2020 Pediatric Rheumatology Symposium
Experience with and Management of HLH-like Toxicities Following Chimeric Antigen Receptor T-Cell Therapy for Treatment of Relapsed/Refractory Pre-B ALL
Amanda Ombrello¹, Bonnie Yates ², Haneen Shalabi ², Terry Fry ³ and Nirali Shah ², ¹National Human Genome Research Institute/National Institutes of Health, Bethesda, ²National Cancer Institute/National Institutes of Health, Bethesda, ³University of Colorado, Denver/Children's Hospital Colorado, Denver
Background/Purpose: Chimeric antigen receptor T-cell (CAR-T) therapy is a highly effective form of adoptive cell immunotherapy combining antigen specific targeting capabilities with T-cell based cytotoxicity.…
Abstract Number: 011 • 2020 Pediatric Rheumatology Symposium
Chronic Non-bacterial Osteomyelitis (CNO): Correlation Between Clinical and Radiological Findings
Martina Capponi ¹, Denise Pires Marafon ², Flaminia Rivosecchi ¹, Manuela Pardeo², Fabrizio De Benedetti ² and Antonella Insalaco ², ¹IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy
Background/Purpose: Due to the lack of widely accepted diagnostic criteria or disease biomarkers, chronic non-bacterial osteomyelitis (CNO) remains a diagnosis of exclusion. Whole-body MRI (WB-MRI) has…
Abstract Number: 012 • 2020 Pediatric Rheumatology Symposium
Pediatric Antiphospholipid Syndrome: Clinical Features and Therapeutic Interventions in a Series of 22 Cases
Jacqueline Madison¹ and Jason Knight ¹, ¹University of Michigan, Ann Arbor
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a thromboinflammatory disease classically defined by the presence of circulating antiphospholipid antibodies and either thrombotic events or pregnancy morbidity.…
Abstract Number: 013 • 2020 Pediatric Rheumatology Symposium
A Preliminary Data-driven Anatomic Classification for Childhood Takayasu Arteritis (cTA)
Ellen Go¹, Simon Eng ², David Cabral ³ and Rae Yeung ¹, ¹The Hospital for Sick Children, Toronto, Canada, ²Toronto, Canada, ³BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada
Background/Purpose: The pattern of arterial involvement and disease severity varies in those affected with cTA. Distinct imaging patterns that have some congruence with clinical phenotype…
Abstract Number: 014 • 2020 Pediatric Rheumatology Symposium
Successful Validation of a Rapid Point-of-care Test for Serum Calprotectin (MRP8/14) as Biomarker in Juvenile Idiopathic Arthritis
Dirk Foell¹, Carolin Park ², Linda Ziegler ², Dirk Holziner ³, Kirsten Minden ⁴, Renato Cotti ⁵ and Jakob Weber ⁵, ¹University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany, ²University of Muenster, Muenster, Germany, ³University of Essen, Essen, Germany, ⁴Berlin, Germany, ⁵Buehlmann Laboratories, Schoenenbuch, Switzerland
Background/Purpose: Treat-to-target strategies are established for the therapeutic approach to patients suffering from juvenile idiopathic arthritis (JIA). Another proposed therapeutic concept in pediatric rheumatology involves…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].